Abstract:Diabetes, a chronic disease necessitating long-term treatment and self-management, presents significant challenges for patients who spend most of their treatment time outside of hospitals. The potential of digital therapeutics for diabetes has garnered recognition from different organizations. Although some prior studies have demonstrated successful reductions in patients' blood glucose levels and body weight through digital diabetes programs, many studies were limited by including prediabetes patients, patients treated with mostly premixed insulin or evaluating user engagement outcomes rather than clinical outcomes. Consequently, limited evidence remains regarding the effectiveness of health management mobile applications specifically designed for T2DM patients initiating BI (basal insulin). This prospective observational study evaluated the effectiveness and safety of the TRIO optimal health management program for patients with type 2 diabetes mellitus (T2DM) initiating basal insulin therapy in a real-world setting. Patients aged 18 to 85 years with inadequate glycemic control (baseline HbA1c ≥7.0%) starting basal insulin therapy were enrolled from outpatient and inpatient. The study duration was 3 months, with health education and phone-based follow-up assessments. Data collected included patient characteristics, medical history, baseline diabetes conditions, treatment compliance, glycemic control, and safety indicators. A total of 199,431 patients were included and 118,134 patients completed the 3-month follow-up. The mean baseline HbA1c was 9.2%, the mean duration of diabetes was 7.3 years, and 80.4% of patients were using basal insulin with oral antihyperglycemic drugs. After the intervention, mean HbA1c decreased by -2.59% from baseline, with 55.6% achieving the target HbA1c level of <7.0%. Patients who set a lower fasting plasma glucose (FPG) goals (<6.1 mmol/L) showed greater HbA1c reductions and higher target achievement compared to those with FPG goal ≥6.1 mmol/L. Factors such as complications, diabetes duration, and baseline HbA1c levels influenced the magnitude of HbA1c reduction. The presence of complications, shorter diabetes duration, higher baseline HbA1c was significantly associated with increased hypoglycemia incidence risk. The TRIO optimal health management program effectively improved glycemic control in patients with T2DM initiating basal insulin therapy. Individualized treatment approaches considering patient characteristics and glycemic goals are vital for optimal outcomes. This is a real-world study of initiating basal insulin therapy.

Use of the Community-Derived Open-Source Automated Insulin Delivery Loop System in Type 2 Diabetes

518-P: User Experiences with Loop, an Open-Source Automated Insulin Delivery (AID) System

Closed-Loop Insulin Therapy for People With Type 2 Diabetes Treated With an Insulin Pump: A 12-Week Multicenter, Open-Label Randomized, Controlled, Crossover Trial

The impact of using a closed-loop system on food choices and eating practices among people with Type 1 diabetes: a qualitative study involving adults, teenagers and parents

Evaluation of hybrid closed-loop insulin delivery system in type 1 diabetes in real-world clinical practice: One-year observational study

Lived Experience of Fully Closed-Loop Insulin Delivery in Adults with Type 1 Diabetes

Lived experience of older adults with type 1 diabetes using closed-loop automated insulin delivery in a randomised trial

Safety Event Outcomes and Glycemic Control with a Hybrid Closed-Loop System Used by Chinese Adolescents and Adults with Type 1 Diabetes Mellitus

Prevalence, safety and metabolic control among Danish children and adolescents with Type 1 Diabetes using Open-Source Automated Insulin Delivery Systems

Performance of an Automated Insulin Delivery System: Results of Early Phase Feasibility Studies

Real-Life Use of Automated Insulin Delivery in Individuals With Type 2 Diabetes

Adolescents’ Experiences of Using a Smartphone Application Hosting a Closed-loop Algorithm to Manage Type 1 Diabetes in Everyday Life: Qualitative Study

Effect of 6 months of hybrid closed-loop insulin delivery in adults with type 1 diabetes: a randomised controlled trial protocol

Hybrid Closed Loop Systems Improve Glycemic Control and Quality of Life in Historically Minoritized Youth with Diabetes

Advanced Hybrid Closed Loop in Adult Population With Type 1 Diabetes: A Substudy From the ADAPT Randomized Controlled Trial in Users of Real-Time Continuous Glucose Monitoring

Better TIR, HbA1c, and less hypoglycemia in closed-loop insulin system in patients with type 1 diabetes: a meta-analysis

Real-World Evidence of Omnipod® 5 Automated Insulin Delivery System Use in 69,902 People with Type 1 Diabetes

Closed-Loop Therapy and Sleep in Young People Newly Diagnosed With T1D and Their Parents

Use of insulin pumps and closed-loop systems among people living with diabetes: A narrative review of clinical and cost-effectiveness to enable access to technology and meet the needs of payers

Benefits and Challenges of Current Closed-Loop Technologies in Children and Young People With Type 1 Diabetes

Effectiveness and Safety of the TRIO Optimal Health Management Program in Patients with Type 2 Diabetes Mellitus (T2DM): A Real-World Study of Initiating Basal Insulin Therapy (Preprint)